[193 Pages Report] The Real World Evidence Solution Market size was estimated at USD 1.38 billion in 2023 and expected to reach USD 1.56 billion in 2024, at a CAGR 14.09% to reach USD 3.47 billion by 2030.
The real world evidence (RWE) solutions enable healthcare organizations, government agencies, and pharmaceutical companies to analyze and utilize real-world data. This data, which includes information collected outside of traditional clinical trials such as electronic health records (EHR), insurance claims, patient registries, and mobile devices, is proving to be invaluable for understanding the effectiveness, safety, and value of healthcare interventions in day-to-day clinical practice. The rise in R&D by pharmaceutical companies has led to an increase in the adoption of RWE solutions for cost-effective drug development and shorter time-to-market. Regulatory bodies are increasingly acknowledging the value of RWE in understanding post-market drug and device usage, which encourages market growth. The growing healthcare industry's shift towards value-based care has promoted the use of RWE solutions to demonstrate the effectiveness of treatments. Data privacy & security concerns with real world evidence (RWE) solutions hampers the growth of the market. Developing advanced analytical models and algorithms to extract meaningful insights from diverse and large datasets and creating user-friendly platforms that accommodate complex needs are expected to create a platform for market growth.
In real-world evidence solutions, the data set component refers to the collection of real-world data (RWD) that can be used to generate real-world evidence (RWE). These data sets are derived from various sources such as claims and billing activities, electronic health records (EHRs), product and disease registries, patient-generated data including in-home-use settings, and data gathered from sources that can inform on health status, such as mobile devices. The services component of real-world evidence solutions encompasses the various offerings provided by solution providers to assist clients in generating and leveraging real-world evidence. Services can range from data analytics and processing to consultation on the design and implementation of real-world studies. Additional services may include regulatory support to ensure compliance with applicable guidelines, advanced analytics, data interpretation, and strategic planning.
Biopharmaceutical companies leverage RWE solutions to support drug development, market access strategies, and post-market surveillance. They need solutions that provide insights into patient outcomes, health economics, and epidemiology. RWE is pivotal in demonstrating the value of drugs to regulators, payers, and healthcare providers. These companies prefer robust data analytics platforms that can handle large datasets from claims data, electronic health records (EHR), and patient registries. Clinical and life sciences organizations such as contract research organizations (CROs) and academic institutions use RWE to validate clinical trial outcomes and to understand disease progression and treatment pathways further. These users value RWE for its ability to identify patient cohorts, enhance recruitment for clinical trials, and establish more effective and cost-efficient treatment protocols. They also look for technologies that can create real-time connections between clinical study data and real-world patient data. Diagnostics & medical device companies are increasingly adopting RWE for product development and market differentiation. For these companies, RWE can inform the design and utility of diagnostics tests and devices, monitor post-marketing safety, and support reimbursement and health technology assessment (HTA) applications. They prioritize solutions that can demonstrate clinical effectiveness and real-world usability and offer comparative analyses against existing standards of care.
In the Americas, the RWE solutions market is expanding with the growing healthcare reform initiatives that fuel demand to leverage RWE for enhanced decision-making. The Americas has seen a surge in patent filings related to advanced data analytics and AI in healthcare. Investment in digital health technologies continues to climb, reflecting the region's pursuit of innovation in healthcare delivery. In the European Union, the adoption of RWE solutions is heterogeneous, with some countries showing more advancement than others. The Euro-centric focus on cost-effectiveness and budget impact for healthcare interventions drives the demand for RWE. The Middle East and Africa showcase a diverse and emerging market for RWE solutions, where healthcare infrastructure and regulatory frameworks are developing at an uneven pace. The Asia Pacific region is a vibrant and fast-growing market for RWE solutions, with countries such as China, Japan, and India playing significant roles. China's latest five-year plan includes a substantial emphasis on healthcare and biotech, showcasing a commitment to invest in digital health and RWE generation. Japan's focus on healthcare innovation is evident in state-funded initiatives aimed at integrating RWE into healthcare delivery and pharmaceutical regulation. In India, increasing digitalization, government initiatives towards universal health coverage, and a growing pharmaceutical sector contribute to the RWE landscape.
The FPNV Positioning Matrix is pivotal in evaluating the Real World Evidence Solution Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Real World Evidence Solution Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Maxis Clinical Sciences Launches Real-World Evidence Solutions Service
Maxis Clinical Sciences launched an innovative Real-World Evidence (RWE) Solutions service that is set to transform the landscape of patient care and clinical studies by seamlessly capturing and unifying Real-World Data (RWD) from a vast array of patient populations and sources for thorough analysis. The company's dedicated commitment lies in diminishing the divide between clinical research initiatives and the forefront of digital advancement, all while prioritizing patient-oriented approaches. The comprehensive RWE Solutions created by Maxis Clinical Sciences are expressly designed to incorporate an extensive range of RWD inputs, including insightful patient-reported outcomes and metrics obtained from wearable technology. [Published On: 2023-10-21]
Target RWE's Cutting-Edge Analytical Solutions Launched to Propel Real-World Evidence Generation
Target RWE announced the introduction of its cutting-edge suite of analytical solutions. Tailored to meet the pressing needs within pharmaceutical product life cycles, these solutions employ advanced epidemiological approaches and robust statistical frameworks to uncover unmet demands and address key strategic queries. Target RWE's latest offerings are powered by an innovative, proprietary analytical platform integral to its Syndicated Science Insights (SSI) solutions, which tackle research hypotheses across varied data sources, including claims and electronic health records. [Published On: 2023-08-23]
Verana Health Launches Real-World Evidence-Driven Solution for Clinical Trial Site Selection
Verana Health unveiled VeraSite, a groundbreaking subscription-based platform designed to streamline the clinical trial site selection process. VeraSite equips trial sponsors and contract research organizations (CROs) with a powerful tool to swiftly identify medical practices that have both clinical proficiency and suitable patient demographics for specific clinical trial protocols. This innovative solution facilitates more aligned site selection, optimizing trial outcomes. Acknowledging the importance of direct communication, VeraSite enables sponsors to contact consenting practices directly, fostering collaboration between researchers and potential trial sites. [Published On: 2023-06-22]
The report delves into recent significant developments in the Real World Evidence Solution Market, highlighting leading vendors and their innovative profiles. These include Aetion, Inc., Cardinal Health, Inc., Certara, L.P., Clinerion Ltd, Clinixir Company Limited, Cognizant Technology Solutions Corp., COREVITAS, LLC., Flatiron Health, Inc., ICON PLC, International Business Machines Corporation, IQVIA Inc., ISPOR, Laboratory Corporation of America Holdings, Mercy Technology Services, Optum, Inc., Oracle Corporation, PAREXEL International Corporation, PerkinElmer Inc., Pharmaceutical Product Development, LLC by Thermo Fisher Scientific Inc., Quantzig, SAS Institute, Inc., Syneos Health, TATA Consultancy Services Limited, Turacoz, and United BioSource LLC.
This research report categorizes the Real World Evidence Solution Market to forecast the revenues and analyze trends in each of the following sub-markets:
- Component
- Data Set
- Claims Data
- Clinical Settings Data
- Patient-Powered Data
- Pharmacy Data
- Services
- Data Set
- Therapeutic Area
- Cardiovascular
- Immunology
- Infectious Diseases
- Neurology
- Oncology
- End-User
- Biopharmaceutical Company
- Clinical & Life Sciences Organization
- Diagnostics or Medical Device Company
- Region
- Americas
- Argentina
- Brazil
- Canada
- Mexico
- United States
- California
- Florida
- Illinois
- New York
- Ohio
- Pennsylvania
- Texas
- Asia-Pacific
- Australia
- China
- India
- Indonesia
- Japan
- Malaysia
- Philippines
- Singapore
- South Korea
- Taiwan
- Thailand
- Vietnam
- Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom
- Americas
- Market Penetration: It presents comprehensive information on the market provided by key players.
- Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
- Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
- Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
- Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
- What is the market size and forecast of the Real World Evidence Solution Market?
- Which products, segments, applications, and areas should one consider investing in over the forecast period in the Real World Evidence Solution Market?
- What are the technology trends and regulatory frameworks in the Real World Evidence Solution Market?
- What is the market share of the leading vendors in the Real World Evidence Solution Market?
- Which modes and strategic moves are suitable for entering the Real World Evidence Solution Market?
- Preface
- Research Methodology
- Executive Summary
- Market Overview
- Market Insights
- Real World Evidence Solution Market, by Component
- Real World Evidence Solution Market, by Therapeutic Area
- Real World Evidence Solution Market, by End-User
- Americas Real World Evidence Solution Market
- Asia-Pacific Real World Evidence Solution Market
- Europe, Middle East & Africa Real World Evidence Solution Market
- Competitive Landscape
- Competitive Portfolio
- List of Figures [Total: 22]
- List of Tables [Total: 380]
- List of Companies Mentioned [Total: 25]
More Representative Patient Population:
Clinical trials are conducted to evaluate the safety and efficacy of a drug. In many cases, the clinical trial patient population does not represent patients in the real world. RWE leverages data from a more diverse patient population, including patients with comorbidities and those who are typically excluded from clinical trials. This provides a more accurate representation of the drug's safety and effectiveness in the real world.
Earlier Detection of Adverse Effects:
Clinical trials are typically conducted on a limited number of patients for a defined period of time. Adverse events after the trial is completed may not be detected for years. RWE can help detect adverse effects earlier by monitoring a drug's performance in the real world.
Cost-Effective Research:
Clinical trials are expensive and time-consuming. Conducting trials in multiple countries and recruiting thousands of patients is a lengthy process that can take years. RWE can provide a cost-effective solution to drug development by leveraging existing data. This can save companies time and money while improving patient outcomes.
Improved Patient Outcomes:
The ultimate goal of drug development is to improve patient outcomes. RWE provides insight into how drugs perform in the real world and can help identify best practices for treatment. For example, if a drug is found to be more effective in a certain patient population, doctors can tailor treatment plans accordingly, leading to better patient outcomes.
Regulatory Acceptance of RWE:
Regulatory agencies around the world are recognizing the potential of RWE. In 2016, the US FDA released guidelines for using RWE in regulatory decision-making. Other agencies, such as EMA and PMDA, have also acknowledged the importance of RWE. As RWE becomes more widely accepted, it will become an increasingly valuable tool in drug development.
Real-world evidence has the potential to revolutionize drug development by providing insight into drug safety and effectiveness in the real world. Leveraging data from sources such as electronic health records and claims data can help identify best practices for treatment and improve patient outcomes. The regulatory recognition of RWE only reinforces the importance of this technology. As we continue to gather more data and refine our RWE approach, we expect to see improved patient outcomes and a more efficient drug development process.
- How big is the Real World Evidence Solution Market?
- What is the Real World Evidence Solution Market growth?
- When do I get the report?
- In what format does this report get delivered to me?
- How long has 360iResearch been around?
- What if I have a question about your reports?
- Can I share this report with my team?
- Can I use your research in my presentation?